Monoamine oxidase inhibitors--is it time to up the TEMPO?
Rascol
Olivier
O
Clinical Investigation Centre, Department of Clinical Pharmacology, INSERM U 455, Toulouse University Hospital, France. rascol@cict.fr <rascol@cict.fr>
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000627:therapeutic use*; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007189:Indans; D008996:Monoamine Oxidase Inhibitors; C031967:rasagiline; D012642:Selegiline; D007980:Levodopa